Zoetis launches feline osteoarthritis drug in Canada and EU
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
July 22, 2026 7:30 AM EDTFirst long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection
PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting... More
